REM1

Summary

REM1 (RRAD and GEM like GTPase 1, HGNC:15922) is a protein-coding gene on chromosome 20q11.21, encoding GTP-binding protein REM 1 (O75628). Promotes endothelial cell sprouting and actin cytoskeletal reorganization.

The protein encoded by this gene is a GTPase and member of the RAS-like GTP-binding protein family. The encoded protein is expressed in endothelial cells, where it promotes reorganization of the actin cytoskeleton and morphological changes in the cells.

Source: NCBI Gene 28954 — RefSeq curated summary.

At a glance

• Clinical variants (ClinVar): 64 total
• MANE Select transcript: NM_014012

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:15922
Approved symbol	REM1
Name	RRAD and GEM like GTPase 1
Location	20q11.21
Locus type	gene with protein product
Status	Approved
Aliases	GES
Ensembl gene	ENSG00000088320
Ensembl biotype	protein_coding
OMIM	610388
Entrez	28954

Gene structure

Transcript identifiers

Ensembl transcripts: 11 — 11 protein_coding

ENST00000201979, ENST00000898142, ENST00000898143, ENST00000898144, ENST00000898145, ENST00000898146, ENST00000954465, ENST00000954466, ENST00000954467, ENST00000954468, ENST00000954469

RefSeq mRNA: 1 — MANE Select: NM_014012 NM_014012

CCDS: CCDS13181

Canonical transcript exons

ENST00000201979 — 5 exons

Exon	Start	End
ENSE00000661077	31477828	31477910
ENSE00000661078	31482287	31482488
ENSE00000859838	31476227	31476785
ENSE00001018614	31484159	31484895
ENSE00001018615	31475288	31475366

Expression profiles

Bgee: expression breadth ubiquitous, 211 present calls, max score 89.84.

FANTOM5 (CAGE): breadth broad, TPM avg 0.9953 / max 84.4682, expressed in 228 samples.

FANTOM5 promoters (1 alternative TSS)

Promoter ID	TPM avg	Samples expressed
183960	0.9953	228

Top tissues by expression

269 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
type B pancreatic cell	CL:0000169	89.84	gold quality
olfactory bulb	UBERON:0002264	89.57	gold quality
pancreatic ductal cell	CL:0002079	89.15	silver quality
endocervix	UBERON:0000458	85.54	gold quality
endometrium epithelium	UBERON:0004811	83.08	gold quality
epithelial cell of pancreas	CL:0000083	82.66	gold quality
mucosa of stomach	UBERON:0001199	82.60	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	82.06	gold quality
left uterine tube	UBERON:0001303	81.22	gold quality
cervix epithelium	UBERON:0004801	81.03	silver quality
cervix squamous epithelium	UBERON:0006922	80.52	gold quality
ectocervix	UBERON:0012249	80.47	gold quality
uterine cervix	UBERON:0000002	80.17	gold quality
subcutaneous adipose tissue	UBERON:0002190	80.01	gold quality
right coronary artery	UBERON:0001625	79.80	gold quality
vena cava	UBERON:0004087	79.62	silver quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	79.60	silver quality
endothelial cell	CL:0000115	79.57	silver quality
body of uterus	UBERON:0009853	79.32	gold quality
ascending aorta	UBERON:0001496	79.02	gold quality
thoracic aorta	UBERON:0001515	78.84	gold quality
tongue squamous epithelium	UBERON:0006919	78.36	gold quality
right uterine tube	UBERON:0001302	78.22	gold quality
esophagogastric junction muscularis propria	UBERON:0035841	78.08	gold quality
diaphragm	UBERON:0001103	78.03	gold quality
aorta	UBERON:0000947	77.99	gold quality
tibial nerve	UBERON:0001323	77.96	gold quality
coronary artery	UBERON:0001621	77.92	gold quality
left coronary artery	UBERON:0001626	77.87	gold quality
gluteal muscle	UBERON:0002000	77.70	silver quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	3.35

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

25 targeting REM1, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4534	99.99	66.58	1907
HSA-MIR-7152-3P	99.97	67.47	849
HSA-MIR-12119	99.87	68.35	1653
HSA-MIR-139-5P	99.80	69.50	1399
HSA-MIR-6764-5P	99.75	67.89	2304
HSA-MIR-6513-3P	99.59	69.77	1102
HSA-MIR-1915-3P	99.58	66.79	1988
HSA-MIR-5701	98.97	69.54	1502
HSA-MIR-29B-1-5P	98.86	68.35	1364
HSA-MIR-1237-3P	98.55	67.65	1423
HSA-MIR-3187-5P	98.36	65.74	1776
HSA-MIR-4436B-3P	98.25	65.26	1494
HSA-MIR-6735-5P	98.24	65.36	1488
HSA-MIR-211-3P	98.14	66.77	1052
HSA-MIR-7843-5P	98.12	65.26	1421
HSA-MIR-4632-5P	97.82	65.38	1470
HSA-MIR-6879-5P	97.77	65.52	1521
HSA-MIR-1285-3P	97.72	67.02	1932
HSA-MIR-5189-5P	97.72	66.96	1814
HSA-MIR-1972	97.67	67.38	1172
HSA-MIR-4771	97.43	67.69	596
HSA-MIR-612	97.26	65.95	1597
HSA-MIR-6860	97.21	66.31	1656
HSA-MIR-4280	96.44	67.69	473
HSA-MIR-10392-3P	88.79	61.83	122

Literature-anchored findings (GeneRIF, showing 2)

• We conclude that Rem is capable of regulating L-type current, that release of Rem block is modulated by cellular kinase pathways, and that the Ca(V)1.2 COOH terminus contributes to Rem-dependent channel inhibition. (PMID:16648185)
• a role for the Rem C terminus in plasma membrane localization through association with phosphatidylinositol lipids. (PMID:17686775)

Cross-species orthologs

2 orthologs

Organism	Symbol	Gene ID
mus_musculus	Rem1	ENSMUSG00000000359
rattus_norvegicus	Rem1	ENSRNOG00000007567

Paralogs (35): RALA (ENSG00000006451), RASL10A (ENSG00000100276), RASD2 (ENSG00000100302), RASL12 (ENSG00000103710), RHEB (ENSG00000106615), RASD1 (ENSG00000108551), RERGL (ENSG00000111404), RAP1A (ENSG00000116473), RASL11A (ENSG00000122035), RAP2C (ENSG00000123728), RAP2A (ENSG00000125249), RRAS (ENSG00000126458), RAP1B (ENSG00000127314), RASL11B (ENSG00000128045), KRAS (ENSG00000133703), RRAS2 (ENSG00000133818), RERG (ENSG00000134533), REM2 (ENSG00000139890), RIT1 (ENSG00000143622), RALB (ENSG00000144118), RIT2 (ENSG00000152214), MRAS (ENSG00000158186), DIRAS3 (ENSG00000162595), GEM (ENSG00000164949), DIRAS2 (ENSG00000165023), RRAD (ENSG00000166592), RHEBL1 (ENSG00000167550), NKIRAS2 (ENSG00000168256), HRAS (ENSG00000174775), DIRAS1 (ENSG00000176490), RAP2B (ENSG00000181467), ERAS (ENSG00000187682), NKIRAS1 (ENSG00000197885), NRAS (ENSG00000213281), RASL10B (ENSG00000270885)

Protein

Protein identifiers

GTP-binding protein REM 1 — O75628 (reviewed: O75628)

Alternative names: GTPase-regulating endothelial cell sprouting, Rad and Gem-like GTP-binding protein 1

All UniProt accessions (1): O75628

UniProt curated annotations — full annotation on UniProt →

Function. Promotes endothelial cell sprouting and actin cytoskeletal reorganization. May be involved in angiogenesis. May function in Ca(2+) signaling.

Subunit / interactions. In vitro, interacts with calmodulin in a calcium-dependent manner.

Tissue specificity. Most highly expressed in the endothelial lining of the blood vessels in uterus and heart. Lower levels found in spleen, lymph node, kidney and testis. Also found in cells with secretory function such as the islets of Langerhans, lobule/duct epithelium in the breast, bile duct epithelium in the liver, surface epithelium in the endometrial glands of the uterus, colon mucosa and acinar cells in the pancreas and the prostate.

Similarity. Belongs to the small GTPase superfamily. RGK family.

RefSeq proteins (1): NP_054731* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001806	Small_GTPase	Family
IPR005225	Small_GTP-bd	Domain
IPR017358	RGK	Family
IPR027417	P-loop_NTPase	Homologous_superfamily
IPR051641	RGK_GTP-binding_reg	Family

Pfam: PF00071

UniProt features (27 total): strand 6, helix 5, sequence variant 3, turn 3, region of interest 2, compositionally biased region 2, binding site 2, chain 1, mutagenesis site 1, sequence conflict 1, modified residue 1

Structure

Experimental structures (PDB)

1 structures.

PDB	Method	Resolution (Å)
2NZJ	X-RAY DIFFRACTION	2.5

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-O75628-F1	71.33	0.36

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Ligand- & substrate-binding residues (2): 87–94; 195–198

Post-translational modifications (1): 51

Mutagenesis-validated functional residues (1):

Position	Phenotype
94	no endothelial cell sprouting.

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 121 (showing top): GOBP_NEGATIVE_REGULATION_OF_TRANSMEMBRANE_TRANSPORT, YAO_HOXA10_TARGETS_VIA_PROGESTERONE_UP, GOBP_MULTICELLULAR_ORGANISMAL_MOVEMENT, GOBP_SKELETAL_MUSCLE_CONTRACTION, GOBP_MONOATOMIC_CATION_TRANSPORT, GOBP_REGULATION_OF_STRIATED_MUSCLE_CONTRACTION, GOBP_NEGATIVE_REGULATION_OF_TRANSPORT, GOBP_REGULATION_OF_MUSCLE_CONTRACTION, GOBP_MUSCLE_CONTRACTION, GOBP_REGULATION_OF_CALCIUM_ION_TRANSMEMBRANE_TRANSPORT, WU_ALZHEIMER_DISEASE_DN, MODULE_99, GOBP_REGULATION_OF_SYSTEM_PROCESS, GOBP_NEGATIVE_REGULATION_OF_CALCIUM_ION_TRANSPORT, GOBP_MUSCLE_SYSTEM_PROCESS

GO Biological Process (3): regulation of skeletal muscle contraction by calcium ion signaling (GO:0014722), negative regulation of calcium ion transmembrane transport via high voltage-gated calcium channel (GO:1904878), negative regulation of high voltage-gated calcium channel activity (GO:1901842)

GO Molecular Function (6): GTPase activity (GO:0003924), calcium channel regulator activity (GO:0005246), calmodulin binding (GO:0005516), GTP binding (GO:0005525), transmembrane transporter binding (GO:0044325), nucleotide binding (GO:0000166)

GO Cellular Component (3): plasma membrane (GO:0005886), T-tubule (GO:0030315), I band (GO:0031674)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
protein binding	2
cellular anatomical structure	2
skeletal muscle contraction	1
regulation of skeletal muscle contraction	1
calcium-mediated signaling	1
calcium ion transmembrane transport via high voltage-gated calcium channel	1
regulation of calcium ion transmembrane transport via high voltage-gated calcium channel	1
negative regulation of calcium ion transmembrane transport	1
high voltage-gated calcium channel activity	1
negative regulation of voltage-gated calcium channel activity	1
ribonucleoside triphosphate phosphatase activity	1
calcium channel activity	1
ion channel regulator activity	1
guanyl ribonucleotide binding	1
purine ribonucleoside triphosphate binding	1
nucleoside phosphate binding	1
heterocyclic compound binding	1
membrane	1
cell periphery	1
sarcolemma	1
sarcomere	1

Protein interactions and networks

STRING

2511 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
REM1	CACNA1C	Q13936	672
REM1	CALML4	Q96GE6	632
REM1	CALM1	P02593	597
REM1	CALML3	P27482	597
REM1	CALML5	Q9NZT1	597
REM1	CALML6	Q8TD86	596
REM1	REM2	Q8IYK8	509
REM1	CACNA1B	Q00975	471
REM1	FRMPD2	Q68DX3	460
REM1	CAV1	Q03135	413
REM1	RASSF5	Q8WWW0	402
REM1	CAV2	P51636	400
REM1	RABIF	P47224	382
REM1	TP53	P04637	381
REM1	RASA1	P20936	380
REM1	SOS1	Q07889	380

IntAct

0 interactions, top by confidence:

BioGRID (12): REM1 (Affinity Capture-MS), REM1 (Far Western), REM1 (Far Western), REM1 (Far Western), REM1 (Far Western), REM1 (Reconstituted Complex), REM1 (Affinity Capture-Western), YWHAZ (Affinity Capture-Western), REM1 (Positive Genetic), REM1 (Affinity Capture-MS), WBSCR22 (Co-fractionation), SULT1A4 (Co-fractionation)

ESM2 similar proteins: A0FGR8, A1DZY4, A5D7J5, O35141, O35929, O75628, O75808, O94103, P01114, P01115, P0C0E4, P27040, P35739, P55040, P55041, P55043, P63032, P63033, P70268, Q00993, Q06AU5, Q13637, Q17QI8, Q3UFB7, Q496Y0, Q5R541, Q63433, Q67VP4, Q6IMB1, Q6P0U3, Q6T310, Q7L0Q8, Q7YS69, Q864R5, Q8HXH0, Q8IYK8, Q8J212, Q8QFP8, Q8VDU1, Q8VEL9

Diamond homologs: A1DZY4, A5A6J7, A6NIZ1, A8NU18, C4YKT4, D3Z8L7, G4MZY8, G4N1S3, O35929, O42785, O75628, O88667, O93856, P01119, P03967, P08645, P08647, P0CQ42, P0CQ43, P0CY32, P10114, P10301, P10833, P11233, P11234, P13856, P15064, P18613, P22124, P22126, P22278, P22279, P22280, P28775, P32252, P32253, P32254, P34726, P34729, P36860

SIGNOR signaling

1 interactions.

A	Effect	B	Mechanism
PRKD1	“up-regulates activity”	REM1	phosphorylation

Disease & clinical

Clinical variants and AI predictions

ClinVar

64 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	48
Likely benign	3
Benign	1

Top pathogenic / likely-pathogenic (0)

SpliceAI

1166 predictions. Top by Δscore:

Variant	Effect	Δscore
20:31476467:G:GT	donor_gain	1.0000
20:31476751:G:T	donor_gain	1.0000
20:31482486:A:T	donor_gain	1.0000
20:31482487:AGGTG:A	donor_loss	1.0000
20:31482488:GGTG:G	donor_loss	1.0000
20:31482489:G:A	donor_loss	1.0000
20:31482490:T:A	donor_loss	1.0000
20:31475455:G:GT	donor_gain	0.9900
20:31476751:G:GT	donor_gain	0.9900
20:31476783:G:GT	donor_gain	0.9900
20:31476783:G:T	donor_gain	0.9900
20:31477819:C:A	acceptor_gain	0.9900
20:31477820:G:A	acceptor_gain	0.9900
20:31477826:A:AG	acceptor_gain	0.9900
20:31477827:G:GA	acceptor_gain	0.9900
20:31477827:GA:G	acceptor_gain	0.9900
20:31477827:GAA:G	acceptor_gain	0.9900
20:31482281:CTGCA:C	acceptor_loss	0.9900
20:31482282:TGCA:T	acceptor_loss	0.9900
20:31482283:GCA:G	acceptor_loss	0.9900
20:31482284:CA:C	acceptor_loss	0.9900
20:31482285:A:C	acceptor_loss	0.9900
20:31482285:AG:A	acceptor_gain	0.9900
20:31482286:G:GC	acceptor_loss	0.9900
20:31482286:GG:G	acceptor_gain	0.9900
20:31482484:GGAAG:G	donor_gain	0.9900
20:31482485:GAAG:G	donor_gain	0.9900
20:31482485:GAAGG:G	donor_gain	0.9900
20:31482489:G:GG	donor_gain	0.9900
20:31484110:C:CA	acceptor_gain	0.9900

AlphaMissense

1899 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
20:31482344:T:G	Y161D	0.998
20:31482365:A:C	S168R	0.998
20:31482367:C:A	S168R	0.998
20:31482367:C:G	S168R	0.998
20:31482444:G:A	G194D	0.998
20:31482451:G:C	K196N	0.998
20:31482451:G:T	K196N	0.998
20:31484174:C:A	A214D	0.998
20:31476705:G:A	G87E	0.997
20:31476705:G:T	G87V	0.997
20:31482347:T:C	S162P	0.997
20:31482378:C:A	A172D	0.997
20:31482435:T:A	I191N	0.997
20:31482438:T:A	L192H	0.997
20:31482438:T:C	L192P	0.997
20:31482444:G:T	G194V	0.997
20:31482448:C:A	N195K	0.997
20:31482448:C:G	N195K	0.997
20:31484207:C:T	S225F	0.997
20:31476720:G:T	G92V	0.996
20:31482435:T:C	I191T	0.996
20:31484161:G:C	G210R	0.996
20:31484189:G:A	C219Y	0.996
20:31484190:T:G	C219W	0.996
20:31484194:T:C	F221L	0.996
20:31484196:C:A	F221L	0.996
20:31484196:C:G	F221L	0.996
20:31476720:G:A	G92E	0.995
20:31476732:T:C	L96S	0.995
20:31482339:T:A	I159N	0.995

dbSNP variants (sampled 300 via entrez): RS1000377779 (20:31480571 C>A), RS1000433540 (20:31474165 T>C), RS1000656023 (20:31480202 G>C), RS1000921203 (20:31479990 A>C,G), RS1001186369 (20:31475486 G>T), RS1001559112 (20:31481798 C>T), RS1001802990 (20:31484095 T>C), RS1002571379 (20:31483038 G>A), RS1002815527 (20:31478679 T>C), RS1003202019 (20:31478250 T>C), RS1003837173 (20:31483690 TCA>T), RS1004200559 (20:31484403 G>C,T), RS1004216646 (20:31484717 C>A,G,T), RS1004490294 (20:31476431 C>G,T), RS1004732525 (20:31478224 G>A)

Disease associations

OMIM: gene MIM:610388 | disease phenotypes:

GenCC curated gene-disease

Mondo (1): long QT syndrome (MONDO:0002442)

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

0 associations (top):

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D008133	Long QT Syndrome	C14.280.067.565; C14.280.123.625; C16.131.240.400.715; C23.550.073.547

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

11 total (human), top 11 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
bisphenol A	increases expression	1
sodium arsenite	increases expression	1
S-(1,2-dichlorovinyl)cysteine	affects response to substance, increases expression	1
CGP 52608	affects binding, increases reaction	1
2-palmitoylglycerol	increases expression	1
Resveratrol	decreases expression, affects cotreatment	1
Benzo(a)pyrene	affects methylation, increases methylation	1
Diethylhexyl Phthalate	decreases expression, increases expression	1
Folic Acid	increases expression	1
Lipopolysaccharides	affects response to substance, increases expression	1
Plant Extracts	affects cotreatment, decreases expression	1

Clinical trials (associated diseases)

66 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT02513940	PHASE4	COMPLETED	Influence of Testosterone Administration on Drug-Induced QT Interval Prolongation and Torsades de Pointes
NCT03834883	PHASE4	COMPLETED	Reducing the Risk of Drug-Induced QT Interval Lengthening in Women
NCT04169100	PHASE4	UNKNOWN	Novel Form of Acquired Long QT Syndrome
NCT04675788	PHASE4	COMPLETED	Novel Approaches for Minimizing Drug-Induced QT Interval Lengthening
NCT01648205	PHASE2	COMPLETED	Long-term Efficacy Study of Sodium Channel Blocker in LQT3 Patients
NCT02412709	PHASE2	UNKNOWN	Long QT Syndrome Screening in Newborns
NCT04581408	PHASE2	COMPLETED	Mutation-specific Therapy for the Long QT Syndrome
NCT00316459	PHASE1	COMPLETED	Study Evaluating the Effects of Multiple Oral Doses of ERB-041 on Cardiac Repolarization in Healthy Subjects
NCT01849003	PHASE1	COMPLETED	Study of the Effect of GS-6615 in Subjects With LQT-3
NCT02365532	PHASE1	COMPLETED	Effect of Oral GS-6615 on Dofetilide-Induced QT Prolongation, Safety, and Tolerability in Healthy Adults
NCT02412098	PHASE1	COMPLETED	Pharmacokinetics of Eleclazine in Adults With Normal and Impaired Hepatic Function
NCT02441829	PHASE1	COMPLETED	Pharmacokinetics of Eleclazine in Adults With Normal and Impaired Renal Function
NCT05759962	PHASE1	COMPLETED	Phase 1 Study of LQT-1213 in Healthy Adults
NCT05906732	PHASE1/PHASE2	TERMINATED	Study of LQT-1213 on QTc-induced Prolongation in Healthy Adult Subjects (Part1) and on Congenital Long QT in Patients Diagnosed With Type 2 or 3 Long QT Syndrome (Part 2).
NCT00005176	Not specified	COMPLETED	Long QT Syndrome-Population Genetics and Cardiac Studies
NCT00005250	Not specified	COMPLETED	Linkage Study of Long QT Syndrome In An Amish Kindred
NCT00005367	Not specified	COMPLETED	Epidemiology of Long QTand Asian Sudden Death in Sleep
NCT00221832	Not specified	UNKNOWN	Molecular Genetic Screening and Identification of Congenital Arrhythmogenic Diseases
NCT00292032	Not specified	COMPLETED	Registry of Unexplained Cardiac Arrest
NCT00335036	Not specified	TERMINATED	Pediatric Lead Extractability and Survival Evaluation (PLEASE)
NCT00399412	Not specified	COMPLETED	ECG Signal Collection From Long QT Syndrome, Wide QRS Complexes, Heart Failure, and Cardiac Resynchronization Patients
NCT00488254	Not specified	COMPLETED	The Long QT Syndrome in Pregnancy
NCT00588965	Not specified	COMPLETED	Effect of Beta-blocker Therapy on QTc Response in Exercise and Recovery in Normal Subjects
NCT01705925	Not specified	COMPLETED	Multicenter Evaluation of Children and Young Adults With Genotype Positive Long QT Syndrome
NCT01903564	Not specified	COMPLETED	Fetal and Neonatal Magnetophysiology
NCT02082431	Not specified	COMPLETED	Determine the Incidence of Long QT Amongst a Large Cohort of Subjects Diagnosed With Unilateral or Bilateral Sensorineural Hearing Loss.
NCT02413450	Not specified	ENROLLING_BY_INVITATION	Derivation of Human Induced Pluripotent Stem (iPS) Cells to Heritable Cardiac Arrhythmias
NCT02425189	Not specified	COMPLETED	The Canadian National Long QT Syndrome Registry
NCT02439645	Not specified	TERMINATED	A Registry to Determine the Clinical and Genetic Risk Factors for Torsade De Pointes
NCT02439658	Not specified	UNKNOWN	Genetics of QT Prolongation With Antiarrhythmics
NCT02549664	Not specified	COMPLETED	Exercise in Genetic Cardiovascular Conditions
NCT02581241	Not specified	COMPLETED	Abnormal QT-Response to the Sudden Tachycardia Provoked by Standing in Individuals With Drug-induced Long QT Syndrome
NCT02680080	Not specified	COMPLETED	Effect of Grapefruit on QT Interval in Healthy Volunteers and Patients With Congenital Long QT Syndrome
NCT02775513	Not specified	UNKNOWN	Metabolism of Patients With Genetically Caused Cardiac Arrhythmia
NCT02814981	Not specified	UNKNOWN	Hydroxyzine and Risk of Prolongation of QT Interval
NCT02876380	Not specified	COMPLETED	Prospective Identification of Long QT Syndrome in Fetal Life
NCT03182777	Not specified	COMPLETED	Safety of Local Dental Anesthesia in Patients With Cardiac Channelopathies
NCT03544918	Not specified	COMPLETED	Prevalence of Congenital Long QT Syndrome and Acquired QT Prolongation in a Hospital Cohort
NCT03642405	Not specified	UNKNOWN	Drug-induced Repolarization ECG Changes
NCT03678311	Not specified	COMPLETED	Long QT Syndrome and Sleep Apnea